Table 3.
Association of angiotensin converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) use with severe COVID-19 outcomes *.
| ACEi/ARB use vs. No ACEi/ARB Use Odds Ratio (95% Confidence Interval); p-Value |
|||
|---|---|---|---|
| Outcome | Adjusted for Age | Adjusted for Age, Sex, Race | Fully adjusted † |
| In hospital death | 1.65 (0.79–3.42); 0.175 | 1.69 (0.79–3.57); 0.170 | 1.85 (0.80–4.29); 0.149 |
| ICU admission | 1.31 (0.77–2.23); 0.317 | 1.26 (0.73–2.19); 0.393 | 0.95 (0.52–1.75); 0.891 |
| Intubation | 1.40 (0.72–2.73); 0.317 | 1.26 (0.63-2.50); 0.502 | 1.00 (0.47–2.12); 0.996 |
* ACEi refers to angiotensin converting enzyme inhibitor. ARB refers to angiotensin II receptor blocker; † Adjusted for age, sex, race, cardiovascular disease, chronic pulmonary disease, diabetes, obesity.